Wedbush reiterated their outperform rating on shares of Catabasis Pharmaceuticals (NASDAQ:CATB) in a research note issued to investors on Friday morning. Wedbush currently has a $4.00 price target on the biotechnology company’s stock.

Several other equities research analysts have also recently commented on CATB. Citigroup reissued a hold rating and issued a $1.50 target price on shares of Catabasis Pharmaceuticals in a research note on Friday, September 29th. Oppenheimer lifted their target price on Catabasis Pharmaceuticals from $4.00 to $7.00 and gave the company an outperform rating in a research note on Thursday, October 5th. CIBC reissued an outperform rating and issued a $7.00 target price (up from $4.00) on shares of Catabasis Pharmaceuticals in a research note on Thursday, October 5th. Cowen reissued a market perform rating and issued a $2.00 target price on shares of Catabasis Pharmaceuticals in a research note on Friday, October 6th. Finally, Zacks Investment Research cut Catabasis Pharmaceuticals from a strong-buy rating to a hold rating in a research note on Monday, October 16th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The stock has a consensus rating of Buy and an average target price of $4.82.

Shares of Catabasis Pharmaceuticals (NASDAQ CATB) opened at $1.65 on Friday. Catabasis Pharmaceuticals has a 52 week low of $1.08 and a 52 week high of $5.51.

Catabasis Pharmaceuticals (NASDAQ:CATB) last released its earnings results on Thursday, November 9th. The biotechnology company reported ($0.31) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.33) by $0.02. The firm had revenue of $0.25 million during the quarter. analysts expect that Catabasis Pharmaceuticals will post -1.41 EPS for the current fiscal year.

Several large investors have recently bought and sold shares of the company. Wedbush Securities Inc. boosted its position in shares of Catabasis Pharmaceuticals by 2,368.6% in the 3rd quarter. Wedbush Securities Inc. now owns 251,802 shares of the biotechnology company’s stock worth $534,000 after purchasing an additional 241,602 shares during the last quarter. Virtu KCG Holdings LLC bought a new position in shares of Catabasis Pharmaceuticals in the 2nd quarter worth $271,000. Oppenheimer & Co. Inc. boosted its position in shares of Catabasis Pharmaceuticals by 40.8% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 169,000 shares of the biotechnology company’s stock worth $358,000 after purchasing an additional 49,000 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new position in shares of Catabasis Pharmaceuticals in the 1st quarter worth $106,000. Institutional investors and hedge funds own 33.14% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was originally published by Watch List News and is owned by of Watch List News. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://www.watchlistnews.com/catabasis-pharmaceuticals-catb-earns-outperform-rating-from-wedbush/1770832.html.

About Catabasis Pharmaceuticals

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Analyst Recommendations for Catabasis Pharmaceuticals (NASDAQ:CATB)

Receive News & Ratings for Catabasis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.